Cargando…

Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity

BACKGROUND: Inflammation is an important pathogenic factor of most malignant tumors. It is essential to understand mechanism underlying inflammation and cancer development, so as to formulate and develop anti-cancer treatment strategies. However, inflammatory-related gene characterization as well as...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Yange, Pang, Hongyan, Yu, Zhiqiang, Wang, Xue, Li, Ping, Zhang, Qianyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124980/
https://www.ncbi.nlm.nih.gov/pubmed/37083272
http://dx.doi.org/10.1080/07853890.2023.2200034
_version_ 1785029942109536256
author Gong, Yange
Pang, Hongyan
Yu, Zhiqiang
Wang, Xue
Li, Ping
Zhang, Qianyun
author_facet Gong, Yange
Pang, Hongyan
Yu, Zhiqiang
Wang, Xue
Li, Ping
Zhang, Qianyun
author_sort Gong, Yange
collection PubMed
description BACKGROUND: Inflammation is an important pathogenic factor of most malignant tumors. It is essential to understand mechanism underlying inflammation and cancer development, so as to formulate and develop anti-cancer treatment strategies. However, inflammatory-related gene characterization as well as risk model construction in prognosis and response chemotherapy or immunotherapy in NSCLC are still remain unclear. METHODS: A total of 1014 lung cancer samples with RNA-seqencing results were download from The Cancer Genome Atlas (TCGA) database. The patient cohort was randomized as a training and test cohorts, and 200 inflammatory-related genes were selected based on previously published data. Consensus clustering and Enrichment and immune function analyses base on Differential expression genes (DEGs) were performed. Prognosis Prediction Model were Constructed and Chemotherapy and immunotherapy sensitivity base on this model were performed. At last, H1299 and HCC827 cells were used to tested the mitoxantrone and oxal iplatin sensitivity after KRT6A knockdown. RESULTS: We identified the inflammatory-related genes from NSCLC datasets to build one prognosis prediction signature based on cluster inflammatory-related genes to lay a certain foundation for distinguishing high-risk NSCLC cases with dismal prognostic outcome. The nomogram provides the AUC values for 1-, 3-, and 5-year overall survival were 0.831, 0.853, and 0.86 in validation cohort. Morover, different sensitivity of immunotherapy or chemotherapy also were classified base on the different risk groups in NSCLC patients, which provided potent clinical reference. At last, targeting KRT6A sensitive to mitoxantrone and oxaliplatin in H1299 and HCC827 cells. CONCLUSIONS: Inflammatory-related gene risk-score is the potential chemotherapeutic and immunotherapeutic biomarker for NSCLC, and targeting KRT6A sensitive to mitoxantrone and oxaliplatin in NSCLC. 1. HIGHLIGHTS: Inflammatory-related genes can lay a certain foundation for distinguishing high-risk NSCLC cases with dismal prognostic outcome. 2. Risk-score base on inflammatory-related genes is positive correlated with CD274, TGFBR1 and TGFB1 expression. 3. Targeting KRT6A sensitive to mitoxantrone and oxaliplatin in H1299 and HCC827 cells.
format Online
Article
Text
id pubmed-10124980
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-101249802023-04-25 Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity Gong, Yange Pang, Hongyan Yu, Zhiqiang Wang, Xue Li, Ping Zhang, Qianyun Ann Med Oncology BACKGROUND: Inflammation is an important pathogenic factor of most malignant tumors. It is essential to understand mechanism underlying inflammation and cancer development, so as to formulate and develop anti-cancer treatment strategies. However, inflammatory-related gene characterization as well as risk model construction in prognosis and response chemotherapy or immunotherapy in NSCLC are still remain unclear. METHODS: A total of 1014 lung cancer samples with RNA-seqencing results were download from The Cancer Genome Atlas (TCGA) database. The patient cohort was randomized as a training and test cohorts, and 200 inflammatory-related genes were selected based on previously published data. Consensus clustering and Enrichment and immune function analyses base on Differential expression genes (DEGs) were performed. Prognosis Prediction Model were Constructed and Chemotherapy and immunotherapy sensitivity base on this model were performed. At last, H1299 and HCC827 cells were used to tested the mitoxantrone and oxal iplatin sensitivity after KRT6A knockdown. RESULTS: We identified the inflammatory-related genes from NSCLC datasets to build one prognosis prediction signature based on cluster inflammatory-related genes to lay a certain foundation for distinguishing high-risk NSCLC cases with dismal prognostic outcome. The nomogram provides the AUC values for 1-, 3-, and 5-year overall survival were 0.831, 0.853, and 0.86 in validation cohort. Morover, different sensitivity of immunotherapy or chemotherapy also were classified base on the different risk groups in NSCLC patients, which provided potent clinical reference. At last, targeting KRT6A sensitive to mitoxantrone and oxaliplatin in H1299 and HCC827 cells. CONCLUSIONS: Inflammatory-related gene risk-score is the potential chemotherapeutic and immunotherapeutic biomarker for NSCLC, and targeting KRT6A sensitive to mitoxantrone and oxaliplatin in NSCLC. 1. HIGHLIGHTS: Inflammatory-related genes can lay a certain foundation for distinguishing high-risk NSCLC cases with dismal prognostic outcome. 2. Risk-score base on inflammatory-related genes is positive correlated with CD274, TGFBR1 and TGFB1 expression. 3. Targeting KRT6A sensitive to mitoxantrone and oxaliplatin in H1299 and HCC827 cells. Taylor & Francis 2023-04-21 /pmc/articles/PMC10124980/ /pubmed/37083272 http://dx.doi.org/10.1080/07853890.2023.2200034 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Oncology
Gong, Yange
Pang, Hongyan
Yu, Zhiqiang
Wang, Xue
Li, Ping
Zhang, Qianyun
Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity
title Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity
title_full Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity
title_fullStr Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity
title_full_unstemmed Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity
title_short Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity
title_sort construction of inflammatory associated risk gene prognostic model of nsclc and its correlation with chemotherapy sensitivity
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124980/
https://www.ncbi.nlm.nih.gov/pubmed/37083272
http://dx.doi.org/10.1080/07853890.2023.2200034
work_keys_str_mv AT gongyange constructionofinflammatoryassociatedriskgeneprognosticmodelofnsclcanditscorrelationwithchemotherapysensitivity
AT panghongyan constructionofinflammatoryassociatedriskgeneprognosticmodelofnsclcanditscorrelationwithchemotherapysensitivity
AT yuzhiqiang constructionofinflammatoryassociatedriskgeneprognosticmodelofnsclcanditscorrelationwithchemotherapysensitivity
AT wangxue constructionofinflammatoryassociatedriskgeneprognosticmodelofnsclcanditscorrelationwithchemotherapysensitivity
AT liping constructionofinflammatoryassociatedriskgeneprognosticmodelofnsclcanditscorrelationwithchemotherapysensitivity
AT zhangqianyun constructionofinflammatoryassociatedriskgeneprognosticmodelofnsclcanditscorrelationwithchemotherapysensitivity